Pub Date : 2026-01-12DOI: 10.1186/s40959-025-00438-y
Linquan Mu, Yi Zhou, Songpu Li, Feng Liu
{"title":"Multiple trait association analysis revealed common genetic loci between lung cancer and heart failure.","authors":"Linquan Mu, Yi Zhou, Songpu Li, Feng Liu","doi":"10.1186/s40959-025-00438-y","DOIUrl":"https://doi.org/10.1186/s40959-025-00438-y","url":null,"abstract":"","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145958827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Among Asian, Native Hawaiian, and Pacific Islanders (ANHPI) in the United States, cancer and cardiovascular disease are the leading causes of death. Colorectal cancer (CRC) is the third most common cancer among ANHPIs, with improving survival rates. However, the risk of cardiovascular disease (CVD) events among ANHPI CRC survivors is unknown, especially within disaggregated ANHPI race and ethnicity groups.
Methods: We estimated the risk of CVD events among ANHPI CRC survivors within the SEER-Medicare database. Composite CVD, heart failure, ischemic heart disease, and stroke/transient ischemic attack were identified using International Classification of Diseases (ICD) diagnostic codes. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for CVD events among ANHPI regional subgroups.
Results: Compared to non-Hispanic White (NHW) CRC survivors, the risk of composite CVD was lower among East and Southeast Asian CRC survivors at > 1 years after initial cancer diagnosis. The risk of composite CVD, heart failure, and ischemic heart disease were lower among East and Southeast Asians for follow-up > 5 years. When compared to East Asians, NHW and Southeast Asian CRC survivors had a higher risk of composite CVD, heart failure, and ischemic heart disease where South Asians had a higher risk of ischemic heart disease.
Conclusions: Within the disaggregated ANHPI race and ethnicity groups of CRC survivors, our results support heterogeneity of incident CVD events. Further research is needed to develop public health interventions to address the disparities in CVD risk, especially among the high-risk groups of South Asian and Southeast Asian CRC survivors.
{"title":"Risk of incident cardiovascular disease events among older Asian, Native Hawaiian, and Pacific Islander colorectal cancer survivors in the United States: a cohort study.","authors":"Timothy Nguyen, Chun-Pin Esther Chang, Randa Tao, Kuangyu Liu, Zuo-Feng Zhang, Mia Hashibe","doi":"10.1186/s40959-025-00440-4","DOIUrl":"https://doi.org/10.1186/s40959-025-00440-4","url":null,"abstract":"<p><strong>Background: </strong>Among Asian, Native Hawaiian, and Pacific Islanders (ANHPI) in the United States, cancer and cardiovascular disease are the leading causes of death. Colorectal cancer (CRC) is the third most common cancer among ANHPIs, with improving survival rates. However, the risk of cardiovascular disease (CVD) events among ANHPI CRC survivors is unknown, especially within disaggregated ANHPI race and ethnicity groups.</p><p><strong>Methods: </strong>We estimated the risk of CVD events among ANHPI CRC survivors within the SEER-Medicare database. Composite CVD, heart failure, ischemic heart disease, and stroke/transient ischemic attack were identified using International Classification of Diseases (ICD) diagnostic codes. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for CVD events among ANHPI regional subgroups.</p><p><strong>Results: </strong>Compared to non-Hispanic White (NHW) CRC survivors, the risk of composite CVD was lower among East and Southeast Asian CRC survivors at > 1 years after initial cancer diagnosis. The risk of composite CVD, heart failure, and ischemic heart disease were lower among East and Southeast Asians for follow-up > 5 years. When compared to East Asians, NHW and Southeast Asian CRC survivors had a higher risk of composite CVD, heart failure, and ischemic heart disease where South Asians had a higher risk of ischemic heart disease.</p><p><strong>Conclusions: </strong>Within the disaggregated ANHPI race and ethnicity groups of CRC survivors, our results support heterogeneity of incident CVD events. Further research is needed to develop public health interventions to address the disparities in CVD risk, especially among the high-risk groups of South Asian and Southeast Asian CRC survivors.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1186/s40959-025-00425-3
Johnny Huang, Rex Lam, Alice Pozza, Hadeel Hassan, Jane E Schneiderman, Paul C Nathan, Luc Mertens, Barbara Cifra
Anthracycline chemotherapy is commonly used to treat cancer in both adult and pediatric patients. While effective, anthracycline treatment is associated with a high risk of cardiotoxicity, often manifesting as a decline in left ventricular function, resulting in long term cardiovascular complications. Aerobic exercise has been studied extensively for its cardioprotective benefits in patients with anthracycline-induced cardiac dysfunction; however, the role of resistance training remains unexplored and controversial due to historical concerns regarding safety. This systematic review examined the existing literature on the effects and safety of resistance training in pediatric and adult cancer patients treated with anthracyclines. A two-part screening process was completed in Covidence (2025), starting with the screening of titles and abstracts, followed by the full-text screening. Eight studies, all incorporating AR-T were reviewed. The findings suggest that AR-T is safe and well-tolerated, with no evidence indicating that resistance training exacerbates cardiac dysfunction. No studies included exclusively pediatric or adolescent patients, limiting the generalizability of the findings to these populations. Randomized controlled trials focused solely on resistance training are needed to inform future clinical guidelines.
{"title":"Evaluating the safety and cardiac impact of resistance training in anthracycline-treated patients: a systematic review.","authors":"Johnny Huang, Rex Lam, Alice Pozza, Hadeel Hassan, Jane E Schneiderman, Paul C Nathan, Luc Mertens, Barbara Cifra","doi":"10.1186/s40959-025-00425-3","DOIUrl":"https://doi.org/10.1186/s40959-025-00425-3","url":null,"abstract":"<p><p>Anthracycline chemotherapy is commonly used to treat cancer in both adult and pediatric patients. While effective, anthracycline treatment is associated with a high risk of cardiotoxicity, often manifesting as a decline in left ventricular function, resulting in long term cardiovascular complications. Aerobic exercise has been studied extensively for its cardioprotective benefits in patients with anthracycline-induced cardiac dysfunction; however, the role of resistance training remains unexplored and controversial due to historical concerns regarding safety. This systematic review examined the existing literature on the effects and safety of resistance training in pediatric and adult cancer patients treated with anthracyclines. A two-part screening process was completed in Covidence (2025), starting with the screening of titles and abstracts, followed by the full-text screening. Eight studies, all incorporating AR-T were reviewed. The findings suggest that AR-T is safe and well-tolerated, with no evidence indicating that resistance training exacerbates cardiac dysfunction. No studies included exclusively pediatric or adolescent patients, limiting the generalizability of the findings to these populations. Randomized controlled trials focused solely on resistance training are needed to inform future clinical guidelines.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145958712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-10DOI: 10.1186/s40959-025-00432-4
Jannek Brauer, Sebastian W Romann, Christian Stengele, Lukas F Entenmann, Daniel Finke, Hugo A Katus, Evangelos Giannitsis, Norbert Frey, Lorenz H Lehmann
{"title":"Prevalence of obstructive coronary artery disease in asymptomatic cancer patients with elevated troponin levels.","authors":"Jannek Brauer, Sebastian W Romann, Christian Stengele, Lukas F Entenmann, Daniel Finke, Hugo A Katus, Evangelos Giannitsis, Norbert Frey, Lorenz H Lehmann","doi":"10.1186/s40959-025-00432-4","DOIUrl":"10.1186/s40959-025-00432-4","url":null,"abstract":"","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":"15"},"PeriodicalIF":3.2,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-10DOI: 10.1186/s40959-026-00444-8
Ahmed Basuoni, Khalid Al-Baimani, Fatma AlKindi, Waleed Dawelbeit, Rawan AlHarrasi, Hadil Al-Sharqi, Nadiya AlKindi, Amany Hany Mohamed Kamel
{"title":"The ROOT-CTRCD study: exploring the relationship of oral health to cancer therapy-related cardiac dysfunction in HER2-positive breast cancer patients.","authors":"Ahmed Basuoni, Khalid Al-Baimani, Fatma AlKindi, Waleed Dawelbeit, Rawan AlHarrasi, Hadil Al-Sharqi, Nadiya AlKindi, Amany Hany Mohamed Kamel","doi":"10.1186/s40959-026-00444-8","DOIUrl":"10.1186/s40959-026-00444-8","url":null,"abstract":"","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":"16"},"PeriodicalIF":3.2,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1186/s40959-025-00441-3
Vibhuti Arya, Lana Mackic, Sara M Telles Langdon, David Y C Cheung, Paris R Haasbeek, Skyler Eastman, Lauren Castagna, Scott Grandy, Stefan S Heinze, Danielle Desautels, Vallerie Gordon, Jeffrey Graham, Susan Green, Debjani Grenier, Christina A Kim, Maclean Thiessen, Marshall Pitz, Davinder S Jassal
{"title":"Can flaxseed \"milk\" prevent anthracycline mediated cardiotoxicity in women with breast cancer (CANFLAX-BC)?","authors":"Vibhuti Arya, Lana Mackic, Sara M Telles Langdon, David Y C Cheung, Paris R Haasbeek, Skyler Eastman, Lauren Castagna, Scott Grandy, Stefan S Heinze, Danielle Desautels, Vallerie Gordon, Jeffrey Graham, Susan Green, Debjani Grenier, Christina A Kim, Maclean Thiessen, Marshall Pitz, Davinder S Jassal","doi":"10.1186/s40959-025-00441-3","DOIUrl":"10.1186/s40959-025-00441-3","url":null,"abstract":"","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":"20"},"PeriodicalIF":3.2,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12870242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1186/s40959-025-00439-x
Vishwa Pakeerathan, Ravi Marwah, Abdul Rahman Mohammed, Justin Smith
Purpose: The purpose of this systematic review and meta-analysis is to explore the utilization of cardioprotective medications in patients treated with RT and assess their impact on cardiovascular and cerebrovascular events.
Materials/methods: A literature search of PubMed, Embase and Scopus was performed in March 2025. Studies of adult patients treated with RT to the head and neck or thoracic regions which investigated the effects of cardioprotective medications (defined as anti-hypertensives, lipid-lowering therapies or anti-thrombotic medications) on the incidence of cardiovascular or cerebrovascular events were eligible for inclusion. Studies that reported the proportion of patients treated with RT who were utilizing cardioprotective medications as recommended by CVD guidelines were also included. Meta-analysis was performed using R with a random effects model.
Results: There were 10 retrospective studies which were eligible for inclusion. Five of the ten studies included patients with head and neck cancer only, whilst two studies included patients with lung cancer and one study included patients with breast cancer alone. Meta-analysis of three studies suggested that patients treated with RT who received statin therapy had a reduced risk of cerebrovascular events (stroke or transient ischemic attack), with a relative risk of 0.74 (95% CI 0.60-0.90). There was no difference in major adverse cardiac events (MACE) for patients treated with RT to the head and neck or thoracic regions who received statin therapy compared to those who did not (relative risk 0.99, 95% CI 0.67 to 1.46, n = 5 studies). A meta-analysis of four studies suggested that 59% (95% CI 35% to 80%) of patients treated with RT not on statin therapy had indications for commencement of these medications.
Conclusion: Current evidence exploring the impact of cardioprotective medications on CVD risk in patients treated with RT is heterogenous and limited to retrospective non-randomized studies. A considerable proportion of patients undergoing RT are not being prescribed cardioprotective medications as suggested by existing CVD guidelines.
目的:本系统综述和荟萃分析的目的是探讨RT患者使用心脏保护药物的情况,并评估其对心脑血管事件的影响。材料/方法:于2025年3月检索PubMed、Embase和Scopus的文献。对接受头颈部或胸部区域RT治疗的成年患者进行的研究,这些研究调查了心脏保护药物(定义为抗高血压、降脂治疗或抗血栓药物)对心脑血管事件发生率的影响,符合纳入标准。报告接受RT治疗的患者使用心血管疾病指南推荐的心脏保护药物的比例的研究也包括在内。采用随机效应模型R进行meta分析。结果:有10项回顾性研究符合纳入条件。十项研究中有五项仅包括头颈癌患者,两项研究包括肺癌患者,一项研究仅包括乳腺癌患者。三项研究的荟萃分析表明,接受他汀类药物治疗的RT患者脑血管事件(中风或短暂性脑缺血发作)的风险降低,相对风险为0.74 (95% CI 0.60-0.90)。接受他汀类药物治疗的头颈部或胸部放疗患者的主要不良心脏事件(MACE)与未接受他汀类药物治疗的患者没有差异(相对危险度0.99,95% CI 0.67至1.46,n = 5项研究)。一项对四项研究的荟萃分析表明,59% (95% CI 35%至80%)接受他汀类药物治疗的RT患者有开始使用这些药物的适应症。结论:目前关于心脏保护药物对接受RT治疗的患者心血管疾病风险影响的证据是异质性的,并且仅限于回顾性的非随机研究。相当一部分接受放射治疗的患者没有按照现有心血管疾病指南的建议服用心脏保护药物。
{"title":"Cardioprotective medications and the incidence of cardiovascular events in patients treated with radiotherapy: a systematic review and meta-analysis.","authors":"Vishwa Pakeerathan, Ravi Marwah, Abdul Rahman Mohammed, Justin Smith","doi":"10.1186/s40959-025-00439-x","DOIUrl":"10.1186/s40959-025-00439-x","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this systematic review and meta-analysis is to explore the utilization of cardioprotective medications in patients treated with RT and assess their impact on cardiovascular and cerebrovascular events.</p><p><strong>Materials/methods: </strong>A literature search of PubMed, Embase and Scopus was performed in March 2025. Studies of adult patients treated with RT to the head and neck or thoracic regions which investigated the effects of cardioprotective medications (defined as anti-hypertensives, lipid-lowering therapies or anti-thrombotic medications) on the incidence of cardiovascular or cerebrovascular events were eligible for inclusion. Studies that reported the proportion of patients treated with RT who were utilizing cardioprotective medications as recommended by CVD guidelines were also included. Meta-analysis was performed using R with a random effects model.</p><p><strong>Results: </strong>There were 10 retrospective studies which were eligible for inclusion. Five of the ten studies included patients with head and neck cancer only, whilst two studies included patients with lung cancer and one study included patients with breast cancer alone. Meta-analysis of three studies suggested that patients treated with RT who received statin therapy had a reduced risk of cerebrovascular events (stroke or transient ischemic attack), with a relative risk of 0.74 (95% CI 0.60-0.90). There was no difference in major adverse cardiac events (MACE) for patients treated with RT to the head and neck or thoracic regions who received statin therapy compared to those who did not (relative risk 0.99, 95% CI 0.67 to 1.46, n = 5 studies). A meta-analysis of four studies suggested that 59% (95% CI 35% to 80%) of patients treated with RT not on statin therapy had indications for commencement of these medications.</p><p><strong>Conclusion: </strong>Current evidence exploring the impact of cardioprotective medications on CVD risk in patients treated with RT is heterogenous and limited to retrospective non-randomized studies. A considerable proportion of patients undergoing RT are not being prescribed cardioprotective medications as suggested by existing CVD guidelines.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":"22"},"PeriodicalIF":3.2,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1186/s40959-025-00397-4
Aleksandra M Sobiborowicz-Sadowska, Katarzyna Kamińska, Dorota Sztechman, Katarzyna Matusik, Łukasz Koperski, Karol Borensztejn, Agnieszka Cudnoch-Jędrzejewska
Introduction: Anthracycline-induced cardiotoxicity (AIC) is a serious complication of chemotherapy, and there is a need for cost-effective biomarkers to enable risk stratification. Serum neprilysin (sNEP) has been investigated as a biomarker in various cardiovascular conditions, but its role in AIC has not been evaluated.
Methods: Twelve-week-old Sprague-Dawley rats received intraperitoneal doxorubicin (DOX) either as a single 20 mg/kg dose (acute model, n = 8), four weekly doses of 5 mg/kg (chronic model, n = 11), or saline (controls, n = 8 for each model). Echocardiography was performed at baseline and on the final study day. Blood and left ventricular (LV) tissue were collected within 24 h (acute model) or one week (chronic model) after the last injection. NEP protein and mRNA expression were measured in LV tissue, and sNEP concentrations were determined in serum.
Results: In the chronic AIC model, LV NEP protein expression was significantly reduced compared with controls (982.56 ± 90.57 vs. 1132.86 ± 132.30 ng/L, p < 0.05). In the acute model, sNEP levels showed a strong positive correlation with the severity of LV cardiomyocyte vacuolization (rs = 0.81, p < 0.05). In the chronic model, sNEP levels were strongly and negatively correlated with cardiac output (r = - 0.91, p < 0.05).
Conclusions: Chronic DOX exposure reduces LV NEP protein expression. Elevated serum sNEP is associated with greater early cardiomyocyte injury, while in chronic AIC, it correlates with a more severe decline in cardiac output. These findings suggest sNEP may be a potential biomarker for AIC.
{"title":"Soluble neprilysin is associated with myocardial damage and systolic dysfunction in an animal model of doxorubicin-induced cardiotoxicity.","authors":"Aleksandra M Sobiborowicz-Sadowska, Katarzyna Kamińska, Dorota Sztechman, Katarzyna Matusik, Łukasz Koperski, Karol Borensztejn, Agnieszka Cudnoch-Jędrzejewska","doi":"10.1186/s40959-025-00397-4","DOIUrl":"10.1186/s40959-025-00397-4","url":null,"abstract":"<p><strong>Introduction: </strong>Anthracycline-induced cardiotoxicity (AIC) is a serious complication of chemotherapy, and there is a need for cost-effective biomarkers to enable risk stratification. Serum neprilysin (sNEP) has been investigated as a biomarker in various cardiovascular conditions, but its role in AIC has not been evaluated.</p><p><strong>Methods: </strong>Twelve-week-old Sprague-Dawley rats received intraperitoneal doxorubicin (DOX) either as a single 20 mg/kg dose (acute model, n = 8), four weekly doses of 5 mg/kg (chronic model, n = 11), or saline (controls, n = 8 for each model). Echocardiography was performed at baseline and on the final study day. Blood and left ventricular (LV) tissue were collected within 24 h (acute model) or one week (chronic model) after the last injection. NEP protein and mRNA expression were measured in LV tissue, and sNEP concentrations were determined in serum.</p><p><strong>Results: </strong>In the chronic AIC model, LV NEP protein expression was significantly reduced compared with controls (982.56 ± 90.57 vs. 1132.86 ± 132.30 ng/L, p < 0.05). In the acute model, sNEP levels showed a strong positive correlation with the severity of LV cardiomyocyte vacuolization (rs = 0.81, p < 0.05). In the chronic model, sNEP levels were strongly and negatively correlated with cardiac output (r = - 0.91, p < 0.05).</p><p><strong>Conclusions: </strong>Chronic DOX exposure reduces LV NEP protein expression. Elevated serum sNEP is associated with greater early cardiomyocyte injury, while in chronic AIC, it correlates with a more severe decline in cardiac output. These findings suggest sNEP may be a potential biomarker for AIC.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"12 1","pages":"3"},"PeriodicalIF":3.2,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}